Key facts
- It has raised $16.2M; the latest was Early Stage VC ($7.3M) in Jan 2025.
- Notable investors include Mitsubishi UFJ Capital, SMBC Venture Capital, Mizuho Capital, Nippon Venture Capital, FFG Venture Business Partners — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Neusignal Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Neusignal Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neusignal Therapeutics
Developer of small molecule drugs intended to cure brain diseases and overcome central nervous system diseases. The company engages in the research and development of therapeutic agents for dementia and psychiatric disorders and overcoming central nervous system diseases, enabling patients with brain diseases to solve their various problems related to brain health.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2022
- Employees
- 11
- Website
- neusignal-tx.com/
- Ownership
- Privately Held (backing)
Neusignal Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neusignal Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neusignal Therapeutics in its N-PORT filings yet. We sweep new filings monthly.